Soligenix Files Proxy Materials
Ticker: SNGX · Form: DEFA14A · Filed: May 15, 2024 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | DEFA14A |
| Filed Date | May 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, corporate-governance
Related Tickers: SOLI
TL;DR
SOLI proxy filing dropped, get ready for shareholder votes.
AI Summary
Soligenix, Inc. filed a Definitive Additional Materials proxy statement on May 15, 2024. This filing relates to the company's solicitation of proxies for its upcoming shareholder meeting. The company, previously known as Dor Biopharma Inc. and Endorex Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is a routine but important step for public companies to communicate with shareholders regarding important corporate matters and upcoming votes.
Risk Assessment
Risk Level: low — This is a standard proxy filing, not indicating any immediate financial or operational risk.
Key Players & Entities
- SOLIGENIX, INC. (company) — Registrant
- DOR BIOPHARMA INC (company) — Former Company Name
- ENDOREX CORP (company) — Former Company Name
- IMMUNOTHERAPEUTICS INC (company) — Former Company Name
- 20240515 (date) — Filing Date
FAQ
What type of filing is this for Soligenix, Inc.?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
When was this filing made?
The filing was made on May 15, 2024.
What is Soligenix, Inc.'s primary business sector?
Soligenix, Inc. is in the 'Pharmaceutical Preparations' sector, SIC code 2834.
Has Soligenix, Inc. operated under other names?
Yes, it was formerly known as Dor Biopharma Inc., Endorex Corp., and Immunotherapeutics Inc.
Where is Soligenix, Inc. headquartered?
The company's business and mailing address is 29 Emmons Drive, Suite B-10, Princeton, NJ 08540.
Filing Stats: 153 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-05-15 16:05:38
Filing Documents
- tmb-20240515xdefa14a.htm (DEFA14A) — 10KB
- 0001558370-24-008288.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement. Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement. Definitive Additional Materials. Soliciting Material Pursuant to 240.14a-12 SOLIGENIX, INC. (Name of Registrant as Specified in Its Charter) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. [The following is a post made to the Company's social media pages on Twitter, Facebook, Instagram and LinkedIn on May 15, 2024] Your vote is needed. Please participate in our Annual Meeting of Shareholders today. Go to www.proxyvote.com or call 1-800-690-6903 (have your proxy card available) to vote your shares.